Antifibrotická terapie a její indikace u intersticiální plicní fibrózy

Title in English Antifibrotic therapy and its indications for interstitial pulmonary fibrosis


Year of publication 2022
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Keywords idiopathic pulmonary fibrosis; nintedanib; pirfenidon; progressive fibrosing interstitial lung diseases
Description Idiopathic pulmonary fibrosis and chronic fibrotic interstitial lung disease with progressive phenotype are characterized by fibrotic lung parenchyma. Current antifibrotic treatment does not affect pre-existing lung parenchyma fibrosis, but prevents fibrosis progression and reduces mortality by reducing fibrotization. This work summarizes fibrotic lung processes and their treatment options. © 2022, SOLEN s.r.o.. All rights reserved.

You are running an old browser version. We recommend updating your browser to its latest version.

More info